Abstract 1251P
Background
Neutrality trial aims to analyze the prognostic role of blood biomarkes such as NLR (neutrophils to lymphocytes ratio), SII (Systemic Inflammatory Index-NLR x platelets), dNLR (neutrophil to leukocytes - neutrophil ratio) and LIPI (Lung Immune Prognostic Index) in stage III NSCLC patients (pts) treated with radiochemotherapy (RT-CHT) followed by Durvalumab (Cohort A), and in pts treated with RT-CHT alone (Cohort B).
Methods
NEUTRALITY is a retrospective multicentric observational study (ESR-19-20410). Blood count tests were recorded at the end of RT-CHT for Cohort B and during Durvalumab course for Cohort A. Different cut-offs of NLR, dNLR and SII were considered, based on the median values observed. Three LIPI index groups were analyzed: good (dNLR ≤ 3 and LDH ≤ UNL), intermediate (dNLR>; 3 or LDH ≥ UNL) and poor (dNLR>; 3 and LDH ≥ UNL). We performed a Cox-Regression analysis to correlate these biomarkers to overall survival (OS) and progression-free survival (PFS).
Results
Overall 190 pts (96 in Cohort A and 94 in Cohort B) were enrolled from 35 Italian Centers. Details of pts are shown in the table. For cohort A, we observed a significant correlation between baseline NLR, SII and dNLR with PFS: p 0.017, p 0.03 and p 0.018, respectively. LIPI was found to correlate with PFS too, with a better PFS in the good group, as expected (p 0.04). No correlation was found between these biomarkers and PFS and OS in Cohort B. Table: 1251P
Patients characteristics
| Cohort A patients (%) 96 | Cohort B patients (%) 94 | |
| Sex MF | 62 (64.5%)34 (35.5%) | 66 (70%)28 (30%) |
| Smoke YesNo | 85 (88%)9 (12%) | 85 (90%)9 (10%) |
| Age years MedianRange | 68 y44-83 | 66 y42-84 |
| Histology AdenocarcinomaSquamocellularOthers | 54 (56%)39 (41%)3 (3%) | 49 (52%)39 (41%)6 (7%) |
| PD-L1 expression 01-49≥ 50Not tested | 12 (12.5%)41 (43%)30 (31%)13 (13.5%) | 11 (12%)15 (16%)9 (10%)59 (62%) |
| Stage disease IIIAIIIBIIIC | 35 (36.5%)48 (50%)13 (13.5%) | 39 (41%)44 (47%)11 (12%) |
| ECOG PS 012 | 59 (61.5%)35 (37.5%)1 (1%) | 60 (64%)34 (36%)0 |
Conclusions
Our analysis suggests that blood inflammatory biomarkers can have a prognostic role for stage III NSCLC treated as per Pacific regimen. Further analysis are still ongoing to compare the two cohorts.
Clinical trial identification
ESR-19-20410.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1334P - PET/CT-guided immune checkpoint blocker treatment discontinuation vs treatment continuation in lung cancer long-term responders: A National Network Genomic Medicine Lung Cancer Germany (nNGM) analysis
Presenter: Nikolaj Frost
Session: Poster session 05
1335P - The relationship between nivolumab pharmacokinetics and cancer cachexia biomarkers in patients with metastatic non-small cell lung cancer (NSCLC)
Presenter: Maaike Hofman
Session: Poster session 05
1338P - TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: Fabrizio Citarella
Session: Poster session 05
1339P - Impact of KRAS, STK11, and KEAP1 co-mutations on survival outcome and response to chemoimmunotherapy in patients with metastatic NSCLC
Presenter: Utsav Joshi
Session: Poster session 05
1341P - Exploring the role of the gut microbiome on the efficacy of ipilimumab and nivolumab in advanced non-small cell lung cancer: A prospective observational study
Presenter: Yuki Katayama
Session: Poster session 05
1342P - The efficacy of pembrolizumab vs nivolumab plus ipilimumab in metastatic NSCLC in relation to PD-L1 and TMB status
Presenter: Walid Shalata
Session: Poster session 05
1343P - Adding histology-driven chemotherapy (ChT) to overcome primary resistance to first-line immunotherapy (ICI) in patients (pts) with advanced non-small cell lung cancer (aNSCLC) with PD-L1 ≥50%
Presenter: Andrea De Giglio
Session: Poster session 05
1344P - Plasma proteomics indicated predictive biomarkers for immuno-chemotherapy in stage IIIB-IV non-small cell lung cancer without EGFR/ALK alterations
Presenter: Zhihuang Hu
Session: Poster session 05